Interventional Cardiology最新文献

筛选

英文中文

Familial Hyperlipidemia Caused by Apolipoprotein B Mutation in the Pediatric Amish Population: A Mini Review. 儿童阿米什人群中载脂蛋白B突变引起的家族性高脂血症:一个小型综述。

Interventional Cardiology Pub Date : 2023-01-01

Corey Snyder, Amber L Beitelshees, Devyani Chowdhury

{"title":"Familial Hyperlipidemia Caused by Apolipoprotein B Mutation in the Pediatric Amish Population: A Mini Review.","authors":"Corey Snyder, Amber L Beitelshees, Devyani Chowdhury","doi":"","DOIUrl":"","url":null,"abstract":"Familial Hypercholesterolemia (FH) is an autosomal dominant genetic disorder that causes increased low density lipoprotein cholesterol (LDL-C) levels and a higher risk of premature atherosclerosis and cardiovascular disease (CVD). Common causes of FH include inherited genetic mutations in the LDLR, APOB, and PCSK9 genes. LDLR, APOB, and PCSK9 mutations account for 79%, 5%, and <1% of cases of FH respectively. Apolipoprotein B (ApoB) is the necessary atherogenic lipoprotein which can serve as a determinant of cardiovascular disease including hypercholesterolemia. A founder variant in Apolipoprotein B (APOB p.R3527Q) causes FH and is found in 12% of the Pennsylvania Amish population. This article provides an overview of ApoB metabolism and clinical manifestations associated with APOB mutations. An understanding of the clinical manifestations caused by APOB p.R3527Q can be beneficial for the clinical diagnosis and treatment of FH in the Amish. Based on previous studies, changes in LDL cholesterol (LDL-C), LDL particles (LDL-P), small dense LDL particles, and ApoB levels can be seen among these patients putting them at an increased risk for atherosclerotic issues, vascular hardening, and changes in endothelial function, particularly among homozygous individuals.","PeriodicalId":14469,"journal":{"name":"Interventional Cardiology","volume":"15 Suppl 17","pages":"433-437"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10434815/pdf/nihms-1917021.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10404072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The promise and problems of metabolic-based therapies for heart failure. 以代谢为基础的心力衰竭治疗的前景和问题。

Interventional Cardiology Pub Date : 2021-01-01 Epub Date: 2021-10-04

Dianne M Perez

引用次数: 0

Cost-effectiveness Assessment of Cardiac Interventions: Determining a Socially Acceptable Cost Threshold. 心脏干预的成本-效果评估:确定社会可接受的成本阈值。

Interventional Cardiology Pub Date : 2014-01-01 DOI: 10.2217/ica.13.81

Chete M Eze-Nliam, Zugui Zhang, Sandra A Weiss, William S Weintraub

引用次数: 7